Guidance, NICE advice and quality standards In development
Showing 1 to 3 of 3
| Title | Type | Expected publication date |
|---|---|---|
| Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143] | Technology appraisal guidance | TBC |
| Otilimab for treating moderate to severe rheumatoid arthritis [ID6171] | Technology appraisal guidance | TBC |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |